65
Participants
Start Date
January 8, 2021
Primary Completion Date
March 20, 2024
Study Completion Date
March 20, 2024
PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Midazolam
Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
Rockefeller Outpatient Pavilion (53rd Street), New York
Memorial Sloan Kettering Cancer Center, New York
MSKCC-Westchester (500 Westchester Ave.), Harrison
MSK Commack, Commack
Johns Hopkins University / Johns Hopkins Hospital, Baltimore
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
Duke Eye Center, Durham
Duke University Medical Center, Investigational Chemotherapy Services, Durham
Duke University Medical Center, Durham
Orlando Health Cancer Institute, Orlando
Moffitt Cancer Center, Tampa
Richard M Schulze Family Foundation Outpatient Center at McKinley Campus, Tampa
Tennessee Oncology PLLC, Franklin
Tennessee Oncology PLLC, Nashville
Rabin Medical Center, Petah Tikva
University of Iowa Hospitals and Clinics, Iowa City
Northwestern Medical Group, Chicago
Northwestern Memorial Hospital, Chicago
Siteman Cancer Center - North County, Florissant
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine, St Louis
Siteman Cancer Center - South County, St Louis
Siteman Cancer Center - West County, Creve Coeur
Siteman Cancer Center - St Peters, City of Saint Peters
The University of Texas MD Anderson Cancer Center, Houston
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Rambam Health Care Campus, Haifa
Sheba Medical Center, Ramat Gan
Sourasky Medical Center, Tel Aviv
Hadassah Medical Center, Jerusalem
Massachusetts General Hospital, Boston
Ophthalmic Consultants of Boston Inc (OCB), Boston
Brigham & Women's Hospital, Boston
Imaging: Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Imaging: Brigham and Women's Radiology, Coolidge Corner Imaging, Brookline
Imaging: Brigham and Women's Ambulatory Care, Chestnut Hill
Imaging: Brigham and Women's Mass General Healthcare Center, Foxborough
Dana-Farber Cancer Institute - Chestnut Hill, Newton
Hackensack University Medical Center, Hackensack
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
MSK Monmouth., Middletown
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Pfizer
INDUSTRY